Objective response rates using CT scans can be assessed earlier and for a few malignancies, reliable biomarkers are available (i.e. prostate specific antigen for prostate cancer or complete cytogenic response (CCyR) for chronic myeloid leukaemia (CML)). The gene discussed is KLK3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.